本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
TORONTO, March 11, 2025 /PRNewswire/ -- On March 8, 2025, the public welfare activity of "Celebrating International Women's Day and Caring for Women's Health" and the "Global Press Conference of E7 Protein Detection Kit" were successfully held in Hong Kong, China. This event was hosted by (Canada) Visionary Holdings Inc., Sun Heart Care Charity Foundation, and Targeted Biotech USA, Inc., and co-organized by Yiqijia Group Co., Ltd. and (Canada) Visionary Biotechnology Group, etc. The attending guests included Hong Kong Councilors Hung Kam-in and Kan Ming-tung, Chairman of Sun Heart Care Charity Foundation Cai Fenghua, Chairman of the Board of Directors of Visionary Holdings Inc. Zhou Fan and Director Huang Jun, Chairman of Yiqijia Group Co., Ltd. Wang Lili and CEO Zhong Ruizhen, as well as more than 100 social celebrities. The event also invited Dr. Wang Wei, a world-renowned health management expert, to give a special lecture on women's health. Visionary Holdings Inc. donated E7 protein detection kits worth HK$230,000 to Sun Heart Care Charity Foundation on the spot, and also presented them to all the guests present. This product was well received by the attending guests, who praised it as a blessing for women in Hong Kong and the best choice for eliminating cervical cancer in women at an early stage. Visionary Holdings Inc. is a listed company on the NASDAQ in the United States (stock code: GV) and is the controlling shareholder of Targeted Biotech USA, Inc. GV has always focused on the frontier development in the field of biotechnology, made precise arrangements, and deeply explored technologies and projects with transformative potential. In the track of early cancer screening technology, it keenly captured the unique value and broad prospects of the products of Targeted Biotech USA, Inc. and made a decisive investment. This not only injected strong impetus into the development of Targeted Biotech USA, Inc., but also promoted the technological innovation and industrial upgrading in the entire field of early cancer screening. Sun Heart Care Charity Foundation is a public welfare organization approved by the Hong Kong government. Since its establishment more than 10 years ago, it has made positive contributions to the development of social welfare undertakings in Hong Kong. From educational support for students, support for youth entrepreneurship to care for the elderly, the footprints and voices of Sun Heart Charity Foundation can be found everywhere. Sun Heart Care Charity Foundation has made outstanding contributions to the public welfare undertakings in Hong Kong. In order to celebrate International Women's Day in 2025, care for women, and give back to the society, Sun Heart Charity Foundation, together with GV, held this public welfare activity to protect the health of women in Hong Kong, aiming to enable more women in Hong Kong to enjoy health and a happy life, and to nip cervical cancer in the bud. Targeted Biotech USA, Inc. has achieved remarkable results in the field of early cancer screening. Its core product, the E7 protein home self-test kit, fills a gap in the world and has successfully obtained approvals from China's FDA and the EU's FDA. Currently, it is actively applying for approval from the US FDA. Data shows that there are approximately 2.5 billion women aged 15 to 65 worldwide, and the market potential for cervical cancer screening is huge. This kit uses the world's first rapid home screening and self-test technology for the E7 oncoprotein of cervical cancer. It can accurately detect the transcription and expression of cancer genes in just 15 minutes. Compared with traditional detection methods, it has outstanding advantages such as home self-testing, safety, privacy, and being painless and non-invasive. It increases the accuracy rate of cervical cancer detection from 10-30% to 80-90%. This public welfare activity takes caring for women's health as its core and is committed to promoting the widespread popularization of early cancer screening technology. During the press conference, all parties conducted in-depth discussions on the promotion and application of early cancer screening technology, and planned to promote related products through multiple channels to assist in global cancer prevention and control, and practice the concept of "Eliminating cancer starts with home self-testing". Looking to the future, with the strong support of partners such as GV, Targeted Biotech USA will continue to increase its R&D investment. It plans to launch 5 types of home self-test products for the early screening of cancers and other diseases every year, contributing more to the global health cause and making more contributions to building a healthy Hong Kong and beautiful women in Hong Kong. For more information, please contact: Visionary Holdings Inc.Investor Relations DepartmentEmail: ir@farvision.ca
COMMERCE, Mich., Feb. 6, 2025 /PRNewswire/ -- Nuspire, a leading managed security services provider (MSSP) and a PDI Technologies company, today released its Q4 and Full Year 2024 Cyber Threat Report, providing a comprehensive analysis of the evolving cyber threat landscape. The latest report reveals a significant increase in ransomware extortion publications, a shift in ransomware group dominance, and a continued rise in exploit attempts. Clop Ransomware Surges as Top Threat Actor According to the report, ransomware extortion publications rose by 46% compared to Q3, with Clop ransomware emerging as the most active group, surpassing RansomHub. Clop, known for its double-extortion tactics, leveraged multiple zero-day vulnerabilities throughout Q4, significantly impacting the Professional & Technical Services industry, which remained the most targeted sector. "The sharp increase in ransomware extortions in Q4 2024, particularly from Clop, signals an alarming escalation in cybercriminal operations," said Justin Heard, Director of Security Operations at Nuspire. "Threat actors continue to evolve their tactics, making it critical for organizations to enhance their proactive threat detection capabilities and incident response strategies, and we will continue to watch this in 2025." Key Findings from Nuspire's Q4 2024 Cyber Threat Report Ransomware Trends 2,247 ransomware extortion publications were reported, a 46% increase from Q3 2024. Clop overtook RansomHub as the most active ransomware group, while Akira, Funksec, and Bashe entered the top five. Finance & Insurance emerged as the third-most targeted industry, rising from fifth place in Q3 2024. Exploit Activity Exploit attempts increased by 72% compared to Q3 2024, with 29,180,763 exploit events detected. Hikvision camera vulnerabilities (CVE-2021-36260) and Bash vulnerabilities (CVE-2014-6271) saw significant increases in exploitation attempts (56% and 77%, respectively). Firewall and VPN technologies remain top targets, as cybercriminals seek to bypass perimeter defenses. Dark Web Trends Dark web marketplace listings decreased by 32% from Q3 2024, with 1,316,660 raw log listings and 590,762 credit card listings available for sale. Lumma Stealer, a persistent malware-as-a-service (MaaS) infostealer, continued to thrive, harvesting sensitive data for resale on illicit marketplaces. "Cybercriminals are refining their attack strategies, targeting critical infrastructure and high-value data sources," said Josh Smith, Principal Threat Intelligence Analyst at Nuspire. "Organizations must remain vigilant, employing a combination of AI-driven threat intelligence, robust patch management, and employee security training to mitigate these evolving risks." Mitigation and Security Recommendations To help businesses combat the latest cyber threats, Nuspire recommends: Enhancing endpoint detection and response (EDR) solutions to swiftly detect and contain ransomware attacks. Implementing dark web monitoring to identify compromised credentials and data before they are weaponized. Applying timely system patches to protect against newly discovered exploits, particularly in remote access technologies. Strengthening cybersecurity awareness training to reduce the risk of phishing-based ransomware infections. Access the complete report online at Nuspire's Q4 and Full Year 2024 Cyber Threat Report. About PDI Security and Network SolutionsWith over 25 years of expertise, PDI Security and Network Solutions (formerly known as Nuspire) is redefining cybersecurity and network management through intelligent unification and unparalleled protection. The company delivers fully managed security and network services, including managed detection and response (MDR), endpoint detection and response (EDR), Firewall as a Service, 5G as a Service, and Wi-Fi as a Service. The technology-agnostic platform seamlessly integrates human expertise, advanced AI, and innovative technologies, providing holistic visibility across security and network infrastructure. Staffed by highly trained security experts, PDI 24/7 SOCs help organizations stay ahead of emerging threats while optimizing their technology investments. Learn more about PDI Security and Network Solutions. For more information, contact: claire.spahr@pditechnologies.com
SINGAPORE - Media OutReach Newswire - 19 December 2024 - In the spirit of giving and togetherness, CKS Property Consultants, a property valuation company in Singapore, participated in a heartwarming Christmas celebration at Hope Centre Singapore on 6th December 2024. A Day of Joy and Bonding Hope Centre Singapore is a non-profit voluntary welfare organisation established in 1997. Held at the Centre’s location at 806 King George’s Avenue, the Corporate Social Responsibility (CSR) event saw 30 youths and 30 seniors take part in various engaging activities, supported by CKS staff and the Centre’s volunteers. The participants were divided into groups to enjoy customised activities for youths and seniors. Highlights included lively group games, Christmas craft-making sessions, and a spirited round of BINGO. To foster a sense of community and fun, competitions were held to showcase the best craft creations, with prizes awarded to the winners. Adding a sweet touch to the day, CKS sponsored cupcakes for all attendees, further spreading festive cheer. Seniors also enjoyed a relaxed get-together, sharing conversations and laughter with the volunteers. Supporting a Worthy Cause As part of the community engagement programme, CKS pledged $3,000 to sponsor Christmas gifts for 30 children and to support Hope Centre Singapore’s ongoing programmes. The advance Christmas gifts were a memorable highlight for the youths, who received presents of their choice. “This event was deeply fulfilling for all of us at CKS. It strengthened our team bonds and reminded us of the importance of enhancing the well-being of the community,” said Ednas Wong, Associate Director of the company. Impact and Reflections The event was a success, not only in spreading holiday joy but also in reinforcing CKS’s dedication to making a difference in the community. The interactions with seniors highlighted the importance of giving time and attention to those in need, while the youth activities inspired a spirit of creativity and camaraderie. “By engaging with individuals from all walks of life, we aim to promote inclusivity and kindness, building strong connections within the community. We look forward to organising more meaningful initiatives in the future,” said Ednas Wong, Associate Director of the company. What’s Next CKS aims to continue its efforts in giving back to society with future CSR outreach programmes. Plans include involving staff members’ families in upcoming initiatives to further extend the reach of meaningful activities. How to Support Hope Centre Singapore For those who missed the event but wish to contribute, Hope Centre Singapore welcomes volunteers and donations to support its programmes. Donations received between 9 November 2024 and 31 January 2025 will directly fund the Bread and Bursary With Love programme for the next 2-3 years. For more details about supporting the non-profit organisation, visit Hope Centre Singapore's website. Hashtag: #Volunteersanddonations #CSR #Christmascelebration #Non-profitvoluntarywelfareorganisation #Community #Well-beingThe issuer is solely responsible for the content of this announcement.About CKS Property ConsultantsFormerly known as Cheong Koon Seng Auctioneers & Valuers, CKS Property Consultants specialises in property valuation and estate agency services in Singapore. The valuation team at CKS Property Consultants consists of licensed valuers accredited by the Singapore Institute of Surveyors and Valuers (SISV). Collectively, the team brings over 100 years of combined experience in property valuation.
PARIS, Dec. 13, 2024 /PRNewswire/ -- On this day, HUAWEI hosted GoPaint Worldwide Creating Activity at its Flagship Store Opéra in Paris. This event, led by two talented illustrators, Mayada and Kenza, highlighted the potential of digital art and the ease of accessing creativity through the GoPaint app, available on Huawei MatePad Series. GoPaint Worldwide Creating Activity Lands at the HUAWEI Flagship Store Opéra in Paris During this event, 30 participants explored digital art alongside illustrators Mayada and Kenza. After an introduction to drawing techniques and how to use the GoPaint app on HUAWEI MatePad series, participants were able to create their own artworks, guided by the artists. Each participant left with a unique memento: their personalized drawing printed on a tote bag, an original way to preserve this creative experience. The event also provided an opportunity to test the latest HUAWEI MatePad tablets and explore the features of the GoPaint app, allowing everyone to fully immerse themselves in the world of digital creation. Interactions with the artists enabled participants to learn new techniques and deepen their understanding of digital art. Launched globally across all the brand's tablets, GoPaint is a powerful and intuitive digital painting app offering over 150 preset brushes and more than 80 brush settings. It provides an immersive experience with expressive brushstrokes that perfectly mimic the effect of a pencil on paper. Among the many features offered are innovative brushes like "splatter" and "fluid" brushes, allowing for boundless creativity. The "splatter" brushes, for example, create ink splatters by passing the stylus about 12 mm from the screen and tapping it twice, adding a playful and interactive dimension to the artwork. The app also offers a range of realistic textures, mimicking paper, gold silk, rice paper, and stone, providing an authentic sensation of creating as if drawing on real paper. Finally, thanks to the FangTian Painting Engine 2.0, users enjoy ultra-wide 8K canvases, multiple high-resolution layers and 120 fps high frame rate. GoPaint Worldwide Creating Activity Lands at the HUAWEI Flagship Store Opéra in Paris The goal of GoPaint is to unleash the artist within each of us, allowing anyone to create digital artworks with various canvases and brushes, whether it be ink, oil paint, or watercolor. Throughout the event, each participant had the chance to experience the GoPaint app on Huawei's latest tablets, the HUAWEI MatePad Pro 12.2 and the HUAWEI MatePad 12X, both equipped with the PaperMatte display. This display technology, developed by Huawei, recreates the sensation of working and enjoying content as naturally as on paper, offering a smooth and authentic creation experience. GoPaint Worldwide Creating Activity Lands at the HUAWEI Flagship Store Opéra in Paris The HUAWEI Flagship Store Opéra Paris, an iconic location for the brand in the heart of the capital since 2020, remains committed to offering enriching experiences to its customers. In addition to this digital painting event, the store hosts exclusive events, such as digital art events with GoPaint, photography experiences with HUAWEI XMAGE, and sports events with international ambassador Sir Mo Farah. By leveraging this iconic location and Huawei's technological advancements, the brand continues its mission to offer unique experiences related to art, photography, sports, and health. The HUAWEI Flagship Store Opéra not only provides immersive experiences but also offers comprehensive after-sales service. A dedicated desk, located within the store, is open Monday to Saturday, with a team ready to welcome customers and address all their inquiries. Learn More : MatePad Pro 12.2 PaperMatte: https://consumer.huawei.com/en/tablets/matepad-pro-12-2/ MatePad 12X PaperMatte: https://consumer.huawei.com/en/tablets/matepad-12-x/ GoPaint: https://consumer.huawei.com/en/mobileservices/gopaint/ About Huawei Consumer BG Huawei's products and services are available in more than 170 countries and are used by a third of the world's population. Fourteen R&D centres have been set up in countries around the world, including Germany, Sweden, India, and China. Huawei Consumer BG is one of Huawei's three business units and covers smartphones, PC and tablets, wearables, and cloud services, etc. Huawei's global network is built on over 30 years of expertise in the telecom industry and is dedicated to delivering the latest technological advances to consumers around the world. For more information please visit: http://consumer.huawei.com For regular updates on Huawei Consumer BG, follow us on: Facebook: https://www.facebook.com/huaweimobile/ Twitter: https://twitter.com/HuaweiMobile Instagram: https://www.instagram.com/huaweimobile/ YouTube: https://www.youtube.com/user/HuaweiDeviceCo LinkedIn: https://www.linkedin.com/company/10617746/
PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer Symposium (SABCS). The ADCs (ADC-1 and ADC-2) were engineered using Transcenta's proprietary antibody with site-specifical conjugation of Topoisomerase I Inhibitor payloads and these ADCs demonstrated significantly higher tumor regression activities than MMAE based ADCs in triple-negative breast cancer (TNBC) tumor models. Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, the responses are typically short lived. Thus, there is an urgent need to develop more effective treatments [1]. LIV-1, a member of the zinc transporter family and an estrogen-regulated gene in metastatic breast cancer, is overexpressed in a high prevalence in breast cancer (93%), including both TNBC and hormone receptor positive breast cancer, as well as in melanoma (82%), prostate (72%), ovarian (48%) and uterine (30%) cancer. This makes LIV-1 an attractive cell surface target for developing ADC therapeutics. To develop next generation LIV-1 targeting ADC, Transcenta generated a proprietary novel humanized anti-LIV-1 mAb, 48D6, which displayed unique epitope form benchmark antibody, high binding affinity, specificity, excellent internalization ability. The conjugation method also eliminated FcR binding which resulted in significantly reduced non-specific FcR mediated binding and clearance, and improved pharmacokinetics profile in mice. In vitro studies indicated that breast tumor cells, such as MDA-MB-468 and MCF-7, are more sensitive to Topo I inhibitor than MMAE. Consequently, Transcenta developed two Topo I inhibitor-based ADCs (ADC-1 and ADC-2) using glycotransferase mediated site-specific conjugation. Both ADC-1 and ADC-2 have a drug-to-antibody ratio (DAR) of 4 but with two different Topo I inhibitor payloads. A MMAE based ADC (ADC-3) with the same site-specific conjugation and DAR4 was also synthesized as the control. Although ADC-1 and ADC-2 displayed similar and specific cytotoxic activities against human LIV-1-expressing tumor cells in vitro, as compared to SGN-LIV1A analog (DAR4) or ADC-3, they exhibited much higher maximal tumor cell killing than SGN-LIV1A analog in vivo. In addition, both ADC-1 and ADC-2 demonstrated a strong bystander effect which is important to overcome tumor heterogeneity. In vivo pharmacology study revealed that ADC-1 or ADC-2 exhibited dose-dependent and more potent anti-tumor activities than the SGN-LIV1A analog or ADC-3 in the human LIV-1 transfected MDA-MB-468, a TNBC tumor model. At 3 mg/kg the tumor growth inhibition (TGI)% were: ADC-1 92.4%, ADC-2 94.7%, ADC-3 68.5% and SGN-LIV1A analog 57.0% on Day 30. However, the overall response rate (ORR, 50% reduction of tumor volume from baseline) at 3mg/kg for SGN-LIV1A analog or ADC-3 was 0%, while ORRs of ADC-1 and ADC-2 were 40% and 70%, respectively. At 6 mg/kg, on Day 42, ORRs of ADC-1 and ADC-2 were 90% and 100%, respectively, and complete response (CR) rates were 90% and 100% respectively. The body weight of mice didn't change significantly at either 3 or 6 mg/kg for ADC-1 or ADC-2. "The significantly enhanced anti-tumor activities of ADC-1 and ADC-2 are likely due to the high affinity binding of 48D6 to LIV-1 and the high cytotoxicity of Topo I inhibitor for breast tumor cells." said Dr. Xueming Qian, Chairman of the Board and CEO at Transcenta, "These data warrant further investigation of the lead LIV-1 targeting ADCs (ADC-1 and ADC-2) as potential next-generation therapeutic agent in LIV-1 positive breast cancer and other solid tumors." The 47th San Antonio Breast Cancer Symposium (SABCS) held from December 10 to 13, 2024, in San Antonio, Texas, USA. This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers. Reference: [1] https://www.nature.com/articles/s41586-024-08031-6 About Transcenta Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing. Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Princeton, US and in Beijing, Shanghai and Guangzhou of China, and External Partnering Center in Boston and Los Angeles, US. Transcenta is developing 14 therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Media contact: Bryan Cheng, bryan.cheng@transcenta.com
A12 藝術空間
activity
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
